BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD.

News Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Market Closed - Nyse Other stock markets 04:00:02 2024-04-17 pm EDT			5-day change	1st Jan Change
44.03 ^USD	+0.59%		-13.77%	-70.99%

Apr. 17	Biohaven Launches $200 Million Common Stock Offering	MT
Mar. 04	HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biohaven Launches $200 Million Common Stock Offering	Apr. 17	MT
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology Annual Meeting and Provides Other Business Updates	Apr. 15	AQ
HC Wainwright Adjusts Biohaven's Price Target to $63 From $50, Maintains Buy Rating	Mar. 04	MT
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments	Mar. 01	AQ
TD Cowen Ups Price Target on Biohaven to $55 From $35, Keeps Outperform Rating	Mar. 01	MT
RBC Trims Price Target on Biohaven to $61 From $62, Keeps Outperform, Speculative Risk	Mar. 01	MT
Biohaven Q4 Non-GAAP Net Loss Widens, Shares Fall After-Hours	Feb. 29	MT
RBC Initiates Biohaven at Outperform With Speculative Risk, Sets Price Target at $62, Sees 'Significant Value to Be Unlocked' Over Long Term	Feb. 16	MT
UBS Adjusts Initiates Biohaven Pharmaceutical Holding With Buy Rating, $59 Price Target	Feb. 06	MT
Biohaven Highlights Progress across Innovative Portfolio and Outlines 2024 Anticipated Milestones at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 09	AQ
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	AQ
Biohaven Insider Sold Shares Worth $459,663, According to a Recent SEC Filing	Jan. 02	MT
Baird Starts Biohaven Pharmaceutical With Outperform Rating, $58 Price Target	Dec. 08	MT
Biohaven Presents Expanded EEG and Safety Data for BHV-7000 at the American Epilepsy Society Annual Meeting	Dec. 04	AQ
JPMorgan Adjusts Biohaven Pharmaceutical Price Target to $32 From $26, Maintains Overweight Rating	Nov. 20	MT
Piper Sandler Adjusts Price Target on Biohaven Pharmaceutical to $36 From $29, Keeps Overweight Rating	Nov. 15	MT
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments	Nov. 15	AQ
Biohaven Pharmaceutical Q3 Net Loss Narrows	Nov. 14	MT
Biohaven Presents Preclinical Data Demonstrating Taldefgrobep alfa Reduces Fat and Improves Lean Mass at The Obesity Society's Annual Meeting, ObesityWeek	23-10-17	AQ
Biohaven Pharmaceutical Says Obesity Treatment Candidate Reduces Fat, Improves Lean Mass	23-10-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biohaven Pharmaceutical Holding Company Ltd.

Equities

BHVN

VGG111961055

Summary

Filters